Psoriasis

Psoriasis | Access and Reimbursement | US | 2017

In the past decade, tumor necrosis factor-alpha (TNF-α) inhibitors, AbbVie’s Humira and Amgen’s Enbrel, and Janssen’s interleukin (IL)-12/23 inhibitor Stelara have been leading the U.S…

Psoriasis | Patient Profiler | US | 2017

The psoriasis market has become increasingly lucrative owing to the growing use of biologics in the moderate to severe population who cannot be adequately controlled with topical agents. The…